---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-001060"
form_type: "8-K"
ticker: "VCEL"
cik: "0000887359"
company_name: "Vericel Corp"
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:44:59.707720+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vericel prelim 2025 revenue $276M (+23% Q4); MACI rev $239.5M; GAAP net profitable 2nd year

## Summary
- Total revenue ~$276M; MACI $239.5M (+20%+ YoY 3rd consecutive yr); Burn Care $36.5M.
- Gross margin 74%; adj. EBITDA margin 26%; $200M cash & investments, no debt.
- Q4 set records for MACI implants, implanting surgeons, biopsies; >900 MACI Arthro trained surgeons.
- Completed sales force expansion; initiated MACI Ankle MASCOT trial; new mfg facility on track for 2026.
- CEO cites strong execution, expects continued high revenue growth and profitability improvement in 2026.

## SEC filing metadata
- accession: 0001140361-26-001060
- form_type: 8-K
- ticker: VCEL
- cik: 0000887359
- company_name: Vericel Corp
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887359/000114036126001060/0001140361-26-001060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887359/000114036126001060/ef20062769_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-001060
- JSON: https://secwatch.observer/filing/0001140361-26-001060.json
- Plain text: https://secwatch.observer/filing/0001140361-26-001060.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.